Retatrutide: What the Clinical Trials Actually Found
Retatrutide is a triple-action peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. Here’s what the Phase 2 clinical data actually showed — weight loss results, safety signals, and why researchers are paying attention.
